Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO	Comple	ete if Known	
PE JC186		Application Number	09/719,945
FORMATION DISCLOSURE		Filing Date	02/20/2001
* STATEMENT BY APPLICANT		First Named Inventor	Matthiessen et at CEV
mat is		Group Art Unit	1615
(use as many sheets as necessary) Sheet 1 of 2		Examiner Name	V. Wallace MAY 1 6 200
Sheet 1 of 2	2	Attorney Docket Number	20560-27 TECH CENTER 1600

	U.S. PATENT DOCUMENTS							
		U.S. Patent	Document		Date of Publications of	Pages, Columns, Lines, Where		
Examiner Initials	Cite No. ¹	Number	Kind Code ²	Name of Patentee or Applicant of Cited Document	Cited Documents MM-DD-YYYY	Relevant Passages or Relevant Figures Appear		
85	AA	5,344,918		Dazey, et al.	09/06/1994			

			,	FOREI	GN PATENT DOCUMENTS	3		
			Foreign Patent Doc	ument			Pages, Columns, Lines,	
Examiner Initials	Cite No.1	Office ³	Number ⁴	Kind Code ⁵	Name of Patentee or Applicant of Cited Document	Date of Publications of Cited Documents MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ⁶
55	BA	JP	8-237146	A	Tomokiyo, et al.	03/03/1998		T
35	BB	EP	89118199.2	В	Bonomo, et al.	02/03/1994		T
	BC	EP	96115218.8	Α	Romisch, et al.	02/05/1997		
22	BD	EP	83850180.7	Α	Drettner, et al.	01/02/1985		T.
	BE	JP	10117787	Α	Hagen et al.	05/12/1998		T
25	BF	PCT	94/22905	Α	Jorgensen et al.	10/13/1994		Т
	BG	AT	827/86	В	Vukovich	09/15/1989	-	
<u>S</u>	ВН	DE	195 31 637.1	A	Turecek et al.	03/06/1997		†

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials'	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
55	CA	Chemical Abstracts Volume 100, 1984	T
55	CB	63-Pharmaceuticals Volume 102, 1985	T
SS	CC	S. PAUL BAJAJ, SAMUEL I. RAPAPORT, STEPHEN F. BROWN; <i>Isolation and Characterization of Human Factor VII</i> ; The Journal of Biological Chemistry; Volume 254, No. 1, Pgs. 253-259; Publication date: 12/20/80 and Revised on: 07/21/80	
55	CD	U. HEDNER, S. BJOERN, S.S. BERNVIL, L. TENGBORN, L. STIGENDAHL; Clinical Experience with Human Plasma-Derived Factor VIIa in Patients with Hemophilia A and High Titer Inhibitors; Haemostasis 1989; 19:335-343	T
3	CE	PETER WILDGOOSE and WALTER KISIEL; Activation of Human Factor VII by	T

Examiner		Date	9/./.	_
Signature		Considered	1/11/02	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.)). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				110	imber.	
_		r form 1449A/PTO			Comple	ete if Known
8	F 10180				Application Number	09/719,945
`	" " THE THE	INFORMATION	I DISCLOSUF	RE	Filing Date	02/20/200RFCFI/F
	7, 8	STATEMENT B	BY APPLICAN	IT	First Named Inventor	Matthiessen et al.
4					Group Art Unit	1615 MAY 1 6 2001
CATI	T. TRADE	(use as many she	eets as necessary)		Examiner Name	V. Wallace 20560-2FCH CENTER 1600/290
1,0	Sheet	2	of	2	Attorney Docket Number	20560-27CH CENTER 1600/29(

	<u> </u>	Factors IXa and Xa on Human Bladder Carcinoma Cells; Blood Volume 7 (May 15),	1
		1989, pages 1888-1895	
	CF	ROBERT RADCLIFFE and YALE NEMERSON; Activation and Control of Factor VII	T
(5		by Activated Factor X and Thrombin, Isolation and Characterization of a Single Chain	
フノ		Form of Factor VII; The Journal of Biological Chemistry, Volume 285, No. 9, Issue of	
		January 25, 1975, Pages 388-395	
	CG	ANDERS H. PEDERSON, TORBEN LUND-HANSEN, HENRIK BISGAARD-	T
<i>S</i>		FRANTZEN, FRANK OLSEN, LARS C. PETERSEN; Autoactivation of Human	
		Recombinant Coagulation Factor VII; Biochemistry 1989, 28, 9331-9336	
	CH	SAMPATH SRIDHARA, SHU CHAING, KATHERINE A. HIGH, MORRIS A	T
<<		BLAJCHMAN, BRYAN J. CLARK; Activation of a Recombinant Human Factor VII	
		Structural Analogue Alters Its Affinity of Binding to Tissue Factor; American Journal of	
		Hematology 53:66-71 (1996)	
2/	CI	D. MENACHE and H.R. ROBERTS; Summary Report and Recommendations of the	T
<i>~</i> <		Task Force Members and Consultants; Thrombos. Diathes. haemorrh. (Stuttg.), 1975,	
		33, 645	

		//
Examiner Signature	Lock	Date Considered 9/11/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.)). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JUN 2 7 2001 PTO/SB/08A (10-96)

Please type a plus sign (+) in this pox →⊠

Approved for usertingugh 10/31/99. PMB 0651,0031
Patent and Trademark Office: U.S. DEPARTMENT OF DOOMSTREECE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	n 1449A/PTO			Comple	ete if Known
O %/	١			Application Number	09/719,945
15 mini	ORMATION	N DISCLOSUR	E	Filing Date	02/20/2001
ر الم	ATEMENT I	BY APPLICAN	T	First Named Inventor	Matthiessen et al.
THE TRADEMARY	•			Group Art Unit	1615
& TRAUS	use as many she	eets as necessary)		Examiner Name	V. Wallace
Sheet	1	of	1	Attorney Docket Number	20560-27

<u> </u>		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials'	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
55	AA	URI SELIGSOHN, ARIELA ZIVELIN, SHULAMITH BAR-SHANI; Cold-Promoted Activation of Factor VII: Is It a Problem under Blood Bank Conditions? Haemostasis 13, 186-191 (1983)	T

Examiner Signature	Date Considered 7/1/02	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.)). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.